面对面型式的互动讨论
您可以与业界专家和同业一起，详细讨论研究成果、发展趋势和面临的挑战。
互动讨论组在与潜在合作者建立人脉方面发挥着不可或缺的重要作用。 同时也提供了一个让您分享自己的研究成果，和同业交流彼此的新发想，与同组团队一同思辨解决问题方策的宝贵机会。
8月7日（星期三）, 10:10 AM - 10:55 AM
Breakout Discussions with Networking Coffee Break
TRACK: BISPECIFIC ANTIBODIES FOR CANCER IMMUNOTHERAPY
IN-PERSON BREAKOUT TABLE 1: Challenges and Advancements with Bi and Multi-Specific Antibodies
Moderator: Mark A Tornetta, Vice President, Biologics Discovery, Tavotek Biotherapeutics
- Challenges and solutions in bi- and multi-specific antibody design
- CMC considerations for bi- and multi-specifics
- Advancements in solid tumors and future directions
TRACK: ADVANCES IN CAR T THERAPY
IN-PERSON BREAKOUT TABLE 2: Precision Tailoring CAR T Therapy
Moderator: Julia A Coronella, PhD, VP Immuno Oncology, Immuno Oncology, Poseida Therapeutics Inc
- Considerations for TSCM-based CAR T products
- Autologous vs allogenic therapy
- Viral vs non-viral methodologies
TRACK: THERAPEUTIC CANCER VACCINES
IN-PERSON BREAKOUT TABLE 3: Therapeutic Cancer Vaccines: Key Areas of Research and Innovation Driving Future Success
Moderator: Marion Curtis, PhD, Assistant Professor, Immunology, Mayo Clinic
- What are the most promising strategies to identify and target tumor-specific antigens using cancer vaccines?
- What are the most effective vaccine delivery platforms for cancer therapy?--
- What role do combination therapies play in overcoming immunosuppression and maximizing the effectiveness of cancer vaccines?
- How can cancer vaccines be successfully integrated into standard of care cancer treatment?
8月9日（星期五）, 7:30 AM - 9:00 AM
Breakfast Breakout Discussions
TRACK: EMERGING TECH FOR IO TARGETING & DISCOVERY
IN-PERSON BREAKOUT TABLE 4: Leveraging Biomarker Technologies for Understanding PD-1 Innate and Adaptive Resistance to Inform New Targets and New Combinations
Moderator: Theresa M. LaVallee, PhD, Chief Development Officer, Coherus Biosciences
- Approaches to characterize PD-1 resistance
- Applications of PD-1 resistance characterization for target discovery
- Uncovering novel and next-gen combination treatment approaches through PD-1 findings
IN-PERSON BREAKOUT TABLE 5: Next-Gen
Tech for Improved IO Outcomes Through TAMs
Moderator: Nir Chetrit, PhD, Associate Researcher, Weill Cornell Medicine
- Modulating the tumor-supporting functions of TAMs: current approaches & challenges
- Novel strategies and technologies to overcome limitations of TAM reprogramming
- Scalable TME models and platforms for high-throughput discovery
TRACK: EMERGING CELL-BASED IMMUNOTHERAPIES
IN-PERSON BREAKOUT TABLE 6: Improving Safety to Expand Patient Eligibility for TIL Cell Therapy
Moderator: Madan H. Jagasia, MS, Chief Executive Officer, R&D, Obsidian Therapeutics
- Currently available non-engineered TIL cell therapy requires use of high-dose IL2, which has well-described high-grade toxicity that limits patient eligibility
- Novel approaches are needed to improve the safety of TIL cell therapy to enable a broader patient population to benefit
- Discussion will focus around existing approaches to improve safety as well as potential avenues to explore in future trials
IN-PERSON BREAKOUT TABLE 7: NK Cells: Challenges, Breakthroughs, and Future Directions
Moderator: Nicholas A Zorko, PhD, Assistant Professor, Hematology & Oncology & Transplant, University Of Minnesota Twin Cities
- Challenges with NK cell therapy development
- Pros and cons of NK approaches compared to other cell-based therapeutics
- Applications of NK therapies to solid tumor indications
- Future directions of NK therapies
TRACK: TUMOR MICROENVIRONMENT
IN-PERSON BREAKOUT TABLE 8: Immunosuppression in the Tumor Microenvironment
Moderator: Thierry Guillaudeux, PhD, CSO, Kineta, Inc.
- What are the major drivers of immunosuppression in the tumor microenvironment?
- What are the strategies to overcome immunosuppression?
- What are the promising new targets?
- Which combination strategies should be considered to restore an effective antitumor immune response?
IN-PERSON BREAKOUT TABLE 9: Tumor Microenvironment (TME) Models for Mechanistic Studies
Moderator: Jason Yu, PhD, Senior Postdoctoral Associate, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- What aspects of the TME require ex vivo modeling?
- What are the challenges in modeling tumor immune responses?
- What are the unique advantages of ex vivo TME models?
- How do we advance ex vivo TME models for drug discovery and mechanistic studies?
* 活动内容有可能不事先告知作更动及调整。
On-Demand only通行證依然持續接受申請。
請透過以下詢問按鍵與我們聯絡。
Conference Programs
